FDA approves Novo Nordisk’s Victoza for cardiovascular disease treatment in type 2 diabetes patients
Novo Nordisk’s diabetes medication, Victoza (liraglutide), has gained U.S. Food and Drug Administration (FDA) approval for an expanded use, marking a significant step forward in the treatment of cardiovascular diseases among type 2 diabetes patients. This latest approval allows Victoza to be used to reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular […]